I have been reassessing the adequacy of my investment in RVX. Unlike so many of you around here, I have a short history with this company. I started looking into RVX for less than 6 months. Having said that, I have done my share of reading on the company.

I get that the overall results of the BETonMace trials are either going to take the stock price to new highs or to new lows. I get that Apabelatone has all the makings of a "mini-Humira" if proven effective in all the indications the company is conducting trials on. That's the bullish thesis and it's rather straightforward.

Here goes my devil's advocate view on RVX.

• The medicinal vitues of Apabetalone sound too good to be true. How is it possible for a single molecule to be effective in certains cases of CVD, kidney diseases, and Alzheimer? Wouldn't that be a first?
• If Abetalone is such the wonder drug that the company purports it may be,
  • How is it the majority of scientific papers written about the investigational drug are authored by people affiliated with the company?
  • How is it the company has been unable to secure major/bonafide EU/US based pharma partners by now? It's clear that the company is not set-up to take the drug to the US/EU market on its own.
  • How is it that the company has been unable to secure funding from the medium to large US/CA/EU based fund managers?
  • How is it the company has been unable to find reliable sources of funding at reasonable terms?
  • How is it that there is very little written about Apabetalone in the general press?
• The company has done a really poor job of partnering up with higher educational insitutions, goverment medical research institutions, and not for profit medical research institutions with the objective of having them conduct various clinical studies on RVX-208. I read about the recent partnership with some Canadian university. In my opinion, because of the potential breakthrough status of RVX-208, they should have linked-up with many more institutions in the past 3-5 years. This way, there would have been more indepenently run studies on the molecule.
• Given that the company has a dismal track record when it comes to conducting clinical trials that meet their endpoint, taking RVX-208 through a phase 2 trial using the the current primary and select secondary endpoints would have been the most judicious thing to do.
• The company has burned through more than $300M in over 15-20 years and has never taken any single investigational molecule from pre-clinical studies through a phase 3. If so, how can the company be counted on to bring the prize home ... that is BETonMace is a resounding suscess.. whatever that means.
• The company's management can't ever be counted upon to be open, transparent, professional, fiscally responsible and to deliver on their promises.
• The company's management lacks folks with proven experience in taking drugs from clinical development through commercial development.

The more I think about my concerns regarding RVX as a company, the least comfortable I get about my investment in the company. I will give the above more thought then figure out what's the best thing to do.

All the above is obviously IMOO. I welcome all and any feedback.